The 17.7% dilution is material for a $402M market cap biotech. Monitor for the resale registration statement filing (due ~Sep 15, 2026) and any subsequent selling by investors. The stock may face near-term pressure from the overhang of registered shares.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 25 $3.26entry
- T+1 · 5mo ago +4.60%α +5.32% · $3.41
- T+5 · 5mo ago −9.82%α −11.38% · $2.94
- T+20 · 4mo ago −15.03%α −15.56% · $2.77
- T+60 · 8w ago +8.90%α +5.17% · $3.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Indaptus Therapeutics raised approximately $12 million through a private placement of 20 million shares at $0.60 per share to non-U.S. accredited investors, representing ~17.7% dilution relative to the ~113.2 million shares outstanding. Proceeds are earmarked for working capital, clinical development, and general corporate purposes, with registration rights granted for resale.
Key Financial Metrics
Key Facts
- 20,000,000 shares sold at $0.60/share for ~$12M gross proceeds
- Dilution of ~17.7% based on ~113.2M shares outstanding pre-offering
- Shares sold to non-U.S. accredited investors under Regulation S
- Company granted registration rights for resale; filing due within 90 days of closing
- Use of proceeds: working capital, clinical development, regulatory activities, general corporate purposes
Financial Impact
~$12M gross proceeds with ~17.7% dilution; no commissions paid
Risk Factors
- Dilution overhang from 20M new shares eligible for resale under registration rights
- Potential downward price pressure as investors may sell into the market
- Clinical-stage biotech with no revenue; cash burn may require further financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-029918 |
| Document: form8-k.htm | 0001493152-26-029918 |
| Document: 0001493152-26-029918-index-headers.html | 0001493152-26-029918 |
| Document: 0001493152-26-029918-index.html | 0001493152-26-029918 |
| Document: 0001493152-26-029918.txt | 0001493152-26-029918 |
Track record
20 reports on INDP
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers